Keywords: Johnson & Johnson, Janssen-Cilag, Xeplion, Schizophrenia, Elan, EC approval

European Commission OKs J&J’s Xeplion for schizophrenia

Article | 10 March 2011

Janssen-Cilag International, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), says that Xeplion (paliperidone palmitate, already ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Janssen-Cilag

Johnson & Johnson

Elan

Go to company listing

Related Drugs

Xeplion

Go to drug listing